Ferring International Center SA - Strategic SWOT Analysis Review

Ferring International Center SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The publisher’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA research, develops and markets pharmaceutical products. The company offers products in the fields of reproductive health, endocrinology, gastroenterology, urology, and orthopedics. Its major products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; and Firmagon (degarelix) for prostate cancer. Its pipeline products encompass rHCG for Triggering FFM and rFSH for male infertility for infertility; FE 202767 for Lactation; RBX2660 enema for difficile infection among others. It has production facilities in Europe, Asia, and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.

Ferring International Center SA Key Recent Developments

Jan 07, 2022: Frontiers in microbiology publishes article detailing novel microbiome-based biomarker of post-antibiotic disruptions in gut microbiota
Sep 15, 2021: Fertility House Calls now available nationwide to help women and couples take the first steps to parenthood virtually
Aug 17, 2021: Genedata bioprocess adopted by Ferring Pharmaceuticals

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.